Rankings
▼
Calendar
TEVA Q2 2019 Earnings — Teva Pharmaceutical Industries Limited Revenue & Financial Results | Market Cap Arena
TEVA
Teva Pharmaceutical Industries Limited
$36B
Q2 2019 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$4.3B
-7.7% YoY
Gross Profit
$1.9B
43.7% margin
Operating Income
-$644M
-14.8% margin
Net Income
-$689M
-15.9% margin
EPS (Diluted)
$-0.63
QoQ Revenue Growth
+1.0%
Cash Flow
Operating Cash Flow
-$227M
Free Cash Flow
-$339M
Stock-Based Comp.
$30M
Balance Sheet
Total Assets
$59.4B
Total Liabilities
$44.2B
Stockholders' Equity
$14.1B
Cash & Equivalents
$2.2B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$4.3B
$4.7B
-7.7%
Gross Profit
$1.9B
$2.1B
-8.1%
Operating Income
-$644M
-$14M
-4500.0%
Net Income
-$689M
-$176M
-291.5%
Revenue Segments
Anda
$351M
49%
TREANDA and BENDEKA
$115M
16%
Austedo
$96M
14%
Pro Air
$65M
9%
QVAR
$60M
8%
AJOVY
$23M
3%
Geographic Segments
North America
$1.7B
59%
Europe
$1.2B
41%
← FY 2019
All Quarters
Q3 2019 →